NCT02280083View on ClinicalTrials.gov

A Study to Evaluate the Botulinum Toxin Type A for Injection(HengLi®) in Subjects With Post-stroke Upper Limb Spasticity

PHASE3CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

February 29, 2016

Study Completion Date

September 30, 2016

Conditions
Cerebrovascular Accident
Interventions
DRUG

Botulinum Toxin Type A for Injection

"HengLi002(Botulinum Toxin Type A for Injection,also known as HengLi®)"

DRUG

placebo

placebo

All Listed Sponsors
lead

Lanzhou Institute of Biological Products Co., Ltd

INDUSTRY

NCT02280083 - A Study to Evaluate the Botulinum Toxin Type A for Injection(HengLi®) in Subjects With Post-stroke Upper Limb Spasticity | Biotech Hunter | Biotech Hunter